| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1111/J.1528-1157.1994.TB05939.X |
| P8608 | Fatcat ID | release_s3nbohesvfbwrl2uvjzexaxydq |
| P698 | PubMed publication ID | 8156974 |
| P2093 | author name string | R Riva | |
| F Albani | |||
| A Baruzzi | |||
| P2860 | cites work | The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid | Q34345901 |
| Drug glucuronidation in humans | Q36964610 | ||
| Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications | Q37941910 | ||
| Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects | Q41917893 | ||
| Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction | Q42201560 | ||
| Changes in circulating androgens during short term carbamazepine therapy | Q42532087 | ||
| Possible interaction between oxcarbazepine and an oral contraceptive | Q43807984 | ||
| Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. | Q54728150 | ||
| Dose dependent enzyme induction by oxcarbazepine? | Q57984160 | ||
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | S14-9 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Epilepsia | Q5382969 |
| P1476 | title | Oxcarbazepine: pharmacokinetic interactions and their clinical relevance | |
| P478 | volume | 35 Suppl 3 |
| Q44272770 | Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design |
| Q35617847 | Adjunctive oxcarbazepine in comorbid anxiety and affective disorder with hyponatremic seizure: case analysis and literature review |
| Q55899120 | Adverse effects of antiepileptic drugs |
| Q35213465 | Clinical pharmacokinetics of oxcarbazepine |
| Q35827491 | Clinically relevant drug interactions with antiepileptic drugs |
| Q34432843 | Drug-drug interactions between warfarin and psychotropics: updated review of the literature |
| Q45176499 | Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers |
| Q34254760 | Efficacy, pharmacology, and adverse effects of antiepileptic drugs |
| Q74261516 | Epilepsy |
| Q37426143 | Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology |
| Q40666459 | Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. |
| Q44760714 | How is oxcarbazepine different from carbamazpine? |
| Q43353269 | LC determination of oxcarbazepine and its active metabolite in human serum |
| Q44228274 | Liquid chromatographic determination of oxcarbazepine and its metabolites in plasma of epileptic patients after solid-phase extraction |
| Q31061153 | Management of focal-onset seizures: an update on drug treatment |
| Q33668218 | Metabolism and excretion of mood stabilizers and new anticonvulsants |
| Q28137902 | Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine |
| Q35673095 | New anticonvulsant medication uses in bipolar disorder |
| Q35077748 | New antiepileptic drug therapies. |
| Q35124000 | Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use |
| Q34445634 | Oxcarbazepine in the treatment of epilepsy |
| Q48610473 | Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. |
| Q80397920 | Oxcarbazepine versus Divalproex Sodium for the Continuing Treatment of Mania |
| Q34312353 | Oxcarbazepine: an update of its efficacy in the management of epilepsy |
| Q41271354 | Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations |
| Q41192725 | Pharmacokinetic interactions of the new antiepileptic drugs |
| Q36627204 | Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? |
| Q73954889 | Plasma level monitoring of oxcarbazepine in epileptic patients |
| Q48432442 | Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine |
| Q43515162 | Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). |
| Q44404654 | Safety and tolerability of oxcarbazepine in elderly patients with epilepsy |
| Q34123652 | The importance of drug interactions in epilepsy therapy |
| Q37202953 | The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine |
| Q34458573 | Treating epilepsy in the elderly: safety considerations |
| Q77764410 | Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance |
| Q35893387 | What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? |
| Q50254629 | [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study]. |
Search more.